Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Tonix Pharmaceuticals Holding Corp is a biotechnology business based in the US. Tonix Pharmaceuticals Holding shares (TNXP) are listed on the NASDAQ and all prices are listed in US Dollars. Tonix Pharmaceuticals Holding employs 73 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $1.61 |
|---|---|
| 52-week range | $1.53 - $35.20 |
| 50-day moving average | $2.95 |
| 200-day moving average | $9.69 |
| Wall St. target price | $40.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-7.50 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.61 from 2022-07-01
| 1 week (2022-06-27) | -9.04% |
|---|---|
| 1 month (2022-06-03) | -34.82% |
| 3 months (2022-04-05) | 631.82% |
| 6 months (2022-01-05) | 360.00% |
| 1 year (2021-07-02) | 47.71% |
|---|---|
| 2 years (2020-07-02) | 169.01% |
| 3 years (2019-07-05) | 27.78% |
| 5 years (2017-07-03) | 4.38 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -30.08% |
| Return on equity TTM | -50.95% |
| Profit margin | 0% |
| Book value | $12.04 |
| Market capitalisation | $30.2 million |
TTM: trailing 12 months
We're not expecting Tonix Pharmaceuticals Holding to pay a dividend over the next 12 months.
Tonix Pharmaceuticals Holding's shares were split on a 1:32 basis on 16 May 2022. So if you had owned 32 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tonix Pharmaceuticals Holding shares – just the quantity. However, indirectly, the new 3100% higher share price could have impacted the market appetite for Tonix Pharmaceuticals Holding shares which in turn could have impacted Tonix Pharmaceuticals Holding's share price.
Over the last 12 months, Tonix Pharmaceuticals Holding's shares have ranged in value from as little as $1.53 up to $35.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tonix Pharmaceuticals Holding's is 1.4415. This would suggest that Tonix Pharmaceuticals Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Tonix Pharmaceuticals Holding Corp. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.